Takeda's TAK-721 for eosinophilic esophagitis to get FDA priority review

 

• The FDA has accepted for review Takeda Pharmaceutical's (NYSE:TAK) New Drug Application (NDA) and granted Priority Review for the investigational therapy budesonide oral suspension, TAK-721, designed specifically for eosinophilic esophagitis (EoE).
• If approved, TAK-721 will be the first FDA-approved treatment for the chronic inflammatory disease causing damage to esophagus, and Takeda plans to use the trade name Eohilia.
• https://seekingalpha.com/news/3644391-fda-grants-priority-review-to-takedas-takminus-721-for-eosinophilic-esophagitis